ProCE Banner Activity

My Take: Addressing Patient Reluctance to Switch From an Originator to Its Biosimilar for Treatment of Rheumatic Disease

Clinical Thought
Despite demonstration of comparable efficacy and safety between biosimilars and their originators, some patients avoid this treatment switch. Here’s my take on steps to assuage unfounded patient fears.

Released: February 13, 2018

Expiration: February 12, 2019

No longer available for credit.

Share

Faculty

Jonathan Kay

Jonathan Kay, MD

Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an independent educational grant from

Boehringer Ingelheim

Faculty Disclosure

Primary Author

Jonathan Kay, MD

Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Jonathan Kay, MD, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Bristol‐Myers Squibb, Janssen, Lilly, Merck, Pfizer, Roche, Samsung Bioepis, Sandoz, and UCB and funds for research support paid to his institution from AbbVie, Genentech, Lilly, Pfizer, and UCB.